AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer

E. Jensen-Jarolim; H. J. Bax; R. Bianchini; S. Crescioli; T. R. Daniels-Wells; D. Dombrowicz; E. Fiebiger; H. J. Gould; S. Irshad; J. Janda; D. H. Josephs; F. Levi-Schaffer; L. O’Mahony; G. Pellizzari; M. L. Penichet; F. Redegeld; F. Roth-Walter; J. Singer; E. Untersmayr; L. Vangelista; S. N. Karagiannis

doi:10.1111/all.13311

AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer

E. Jensen-Jarolim^*, H. J. Bax, R. Bianchini, S. Crescioli, T. R. Daniels-Wells, D. Dombrowicz, E. Fiebiger, H. J. Gould, S. Irshad, J. Janda, D. H. Josephs, F. Levi-Schaffer, L. O’Mahony, G. Pellizzari, M. L. Penichet, F. Redegeld, F. Roth-Walter, J. Singer, E. Untersmayr, L. VangelistaS. N. Karagiannis

^*Corresponding author for this work

Research output: Journal article (peer-reviewed) › Review article

55 Citations (Scopus)

Abstract

While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.

Original language	English
Pages (from-to)	328-340
Number of pages	13
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	73
Issue number	2
DOIs	https://doi.org/10.1111/all.13311
Publication status	Published - Feb 2018
Externally published	Yes

Keywords

allergooncology
allergy
cancer
oncoimmunology
tolerance
Immunotherapy/methods
Humans
Hypersensitivity/immunology
Neoplasms/immunology
Desensitization, Immunologic/methods
Immune Tolerance/immunology

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1111/all.13311

Cite this

Jensen-Jarolim, E., Bax, H. J., Bianchini, R., Crescioli, S., Daniels-Wells, T. R., Dombrowicz, D., Fiebiger, E., Gould, H. J., Irshad, S., Janda, J., Josephs, D. H., Levi-Schaffer, F., O’Mahony, L., Pellizzari, G., Penichet, M. L., Redegeld, F., Roth-Walter, F., Singer, J., Untersmayr, E., ... Karagiannis, S. N. (2018). AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy: European Journal of Allergy and Clinical Immunology, 73(2), 328-340. https://doi.org/10.1111/all.13311

@article{5a5f5928a56240efa269acc51ec49f34,

title = "AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer",

abstract = "While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.",

keywords = "allergooncology, allergy, cancer, oncoimmunology, tolerance, Immunotherapy/methods, Humans, Hypersensitivity/immunology, Neoplasms/immunology, Desensitization, Immunologic/methods, Immune Tolerance/immunology",

author = "E. Jensen-Jarolim and Bax, {H. J.} and R. Bianchini and S. Crescioli and Daniels-Wells, {T. R.} and D. Dombrowicz and E. Fiebiger and Gould, {H. J.} and S. Irshad and J. Janda and Josephs, {D. H.} and F. Levi-Schaffer and L. O{\textquoteright}Mahony and G. Pellizzari and Penichet, {M. L.} and F. Redegeld and F. Roth-Walter and J. Singer and E. Untersmayr and L. Vangelista and Karagiannis, {S. N.}",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors. Allergy Published by John Wiley & Sons Ltd.",

year = "2018",

month = feb,

doi = "10.1111/all.13311",

language = "English",

volume = "73",

pages = "328--340",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

Jensen-Jarolim, E, Bax, HJ, Bianchini, R, Crescioli, S, Daniels-Wells, TR, Dombrowicz, D, Fiebiger, E, Gould, HJ, Irshad, S, Janda, J, Josephs, DH, Levi-Schaffer, F, O’Mahony, L, Pellizzari, G, Penichet, ML, Redegeld, F, Roth-Walter, F, Singer, J, Untersmayr, E, Vangelista, L & Karagiannis, SN 2018, 'AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer', Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 2, pp. 328-340. https://doi.org/10.1111/all.13311

TY - JOUR

T1 - AllergoOncology

T2 - Opposite outcomes of immune tolerance in allergy and cancer

AU - Jensen-Jarolim, E.

AU - Bax, H. J.

AU - Bianchini, R.

AU - Crescioli, S.

AU - Daniels-Wells, T. R.

AU - Dombrowicz, D.

AU - Fiebiger, E.

AU - Gould, H. J.

AU - Irshad, S.

AU - Janda, J.

AU - Josephs, D. H.

AU - Levi-Schaffer, F.

AU - O’Mahony, L.

AU - Pellizzari, G.

AU - Penichet, M. L.

AU - Redegeld, F.

AU - Roth-Walter, F.

AU - Singer, J.

AU - Untersmayr, E.

AU - Vangelista, L.

AU - Karagiannis, S. N.

PY - 2018/2

Y1 - 2018/2

N2 - While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.

AB - While desired for the cure of allergy, regulatory immune cell subsets and nonclassical Th2-biased inflammatory mediators in the tumour microenvironment can contribute to immune suppression and escape of tumours from immunological detection and clearance. A key aim in the cancer field is therefore to design interventions that can break immunological tolerance and halt cancer progression, whereas on the contrary allergen immunotherapy exactly aims to induce tolerance. In this position paper, we review insights on immune tolerance derived from allergy and from cancer inflammation, focusing on what is known about the roles of key immune cells and mediators. We propose that research in the field of AllergoOncology that aims to delineate these immunological mechanisms with juxtaposed clinical consequences in allergy and cancer may point to novel avenues for therapeutic interventions that stand to benefit both disciplines.

KW - allergooncology

KW - allergy

KW - cancer

KW - oncoimmunology

KW - tolerance

KW - Immunotherapy/methods

KW - Humans

KW - Hypersensitivity/immunology

KW - Neoplasms/immunology

KW - Desensitization, Immunologic/methods

KW - Immune Tolerance/immunology

UR - http://www.scopus.com/inward/record.url?scp=85040675651&partnerID=8YFLogxK

U2 - 10.1111/all.13311

DO - 10.1111/all.13311

M3 - Review article

C2 - 28921585

AN - SCOPUS:85040675651

SN - 0105-4538

VL - 73

SP - 328

EP - 340

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 2

ER -

AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this